PE20030759A1 - Uso de ureas de benzotiazoles - Google Patents
Uso de ureas de benzotiazolesInfo
- Publication number
- PE20030759A1 PE20030759A1 PE2002001174A PE2002001174A PE20030759A1 PE 20030759 A1 PE20030759 A1 PE 20030759A1 PE 2002001174 A PE2002001174 A PE 2002001174A PE 2002001174 A PE2002001174 A PE 2002001174A PE 20030759 A1 PE20030759 A1 PE 20030759A1
- Authority
- PE
- Peru
- Prior art keywords
- aza
- bicycle
- benzothiazol
- morpholin
- octane
- Prior art date
Links
- 150000003672 ureas Chemical class 0.000 title 1
- 239000002253 acid Substances 0.000 abstract 4
- 150000001875 compounds Chemical class 0.000 abstract 4
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 abstract 2
- TVMXDCGIABBOFY-UHFFFAOYSA-N octane Chemical compound CCCCCCCC TVMXDCGIABBOFY-UHFFFAOYSA-N 0.000 abstract 2
- 102000007471 Adenosine A2A receptor Human genes 0.000 abstract 1
- 108010085277 Adenosine A2A receptor Proteins 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 150000002367 halogens Chemical class 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 201000000980 schizophrenia Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/428—Thiazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/16—Central respiratory analeptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
- C07D277/62—Benzothiazoles
- C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C07D277/82—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
- C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
- C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
- C07D451/06—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
- C07D453/06—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing isoquinuclidine ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/08—Bridged systems
Abstract
SE REFIERE AL USO DE COMPUESTOS DE FORMULA I DONDE R ES ALCOXI, HALOGENO; R1 Y R2 SON H, ALQUILO, CICLOALQUILO, TETRAHIDROPIRAN-4-ILO; R1 Y R2 JUNTO AL N AL QUE ESTAN UNIDOS FORMAN UN ANILLO HETEROCICLICO ELEGIDO ENTRE 2-OXA-5-AZA-BICICLO[2.2.1]HEPTANO, 3-ENDO-HIDROXI-8-AZA-BICICLO[3.2.1]OCTANO, 2-AZA-BICICLO[2.2.2]OCTANO ENTRE OTROS; R' ES H, ALQUILO; X ES -O-, -CH2-; n ES 0-4 Y LAS SALES DE ADICION DE ACIDO FARMACEUTICAMENTE ACEPTABLES. SON COMPUESTOS PREFERIDOS (4-METOXI-7-MORFOLIN-4-IL-BENZOTIAZOL-2-IL)-AMIDA DEL ACIDO (1S,4S)-2-OXA-5-AZA-BICICLO[2.2.1]HEPTANO-5-CARBOXILICO, (4-METOXI-7-MORFOLIN-4-IL-BENZOTIAZOL-2-IL)-AMIDA DEL ACIDO 3-ENDO-HIDRXI-8-AZA-BICICLO[3.2.1]OCTANO-8-CARBOXILICO, (4-METOXI-7-MORFOLIN-4-IL-BENZOTIAZOL-2-IL)-AMIDA DEL ACIDO 2-METIL-1-OXO-2,8-DIAZA-ESPIRO[4.5]DECANO-8-CARBOXILICO, ENTRE OTROS. SE REFIERE TAMBIEN A UN PROCEDIMIENTO PARA LA PREPARACION Y COMPUESTOS INTERMEDIOS. LOS COMPUESTOS MENCIONADOS ESTAN RELACIONADOS CON EL SISTEMA DE RECEPTOR A2A DE ADENOSINA Y SON UTILES PARA EL TRATAMIENTO DE ALZHEIMER, PARKINSON, ESQUIZOFRENIA
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP01129228 | 2001-12-10 |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20030759A1 true PE20030759A1 (es) | 2003-09-05 |
Family
ID=8179478
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2002001174A PE20030759A1 (es) | 2001-12-10 | 2002-12-05 | Uso de ureas de benzotiazoles |
Country Status (20)
Country | Link |
---|---|
US (2) | US6727247B2 (es) |
EP (1) | EP1455792B1 (es) |
JP (1) | JP4245483B2 (es) |
KR (1) | KR100659793B1 (es) |
CN (1) | CN1602196A (es) |
AR (1) | AR037731A1 (es) |
AT (1) | ATE359792T1 (es) |
AU (1) | AU2002356626B2 (es) |
BR (1) | BR0214825A (es) |
CA (1) | CA2469596A1 (es) |
DE (1) | DE60219682T2 (es) |
ES (1) | ES2283652T3 (es) |
GT (1) | GT200200266A (es) |
MX (1) | MXPA04005444A (es) |
PA (1) | PA8559901A1 (es) |
PE (1) | PE20030759A1 (es) |
PL (1) | PL371063A1 (es) |
RU (1) | RU2311905C2 (es) |
TW (1) | TW200409628A (es) |
WO (1) | WO2003049741A1 (es) |
Families Citing this family (46)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ522928A (en) * | 2000-06-21 | 2005-05-27 | F | Benzothiazole derivatives |
EP1231212B1 (en) * | 2001-02-06 | 2006-12-20 | Pfizer Products Inc. | Pharmaceutical compositions for the treatment of disorders of the CNS and other disorders |
US6727247B2 (en) * | 2001-12-10 | 2004-04-27 | Hoffman-La Roche Inc. | Substituted benzothiazole amide derivatives |
EP1522314B1 (en) * | 2002-06-26 | 2014-03-05 | Ono Pharmaceutical Co., Ltd. | Remedies for diseases caused by vascular contraction or dilation |
BRPI0409686A (pt) | 2003-04-24 | 2006-07-04 | Incyte Corp | derivados de aza espiro alcano como inibidores de metaloproteases |
WO2005000842A1 (en) | 2003-05-19 | 2005-01-06 | F. Hoffman-La Roche Ag | Benzothiazole derivatives as adenosine receptor ligands |
ES2307015T3 (es) * | 2003-05-30 | 2008-11-16 | F. Hoffmann-La Roche Ag | Derivados de benzotiazol y su empleo en el tratamiento de enfermedades relacionadas con el receptor de la adenosina a2a. |
CN1871244A (zh) * | 2003-09-19 | 2006-11-29 | 弗·哈夫曼-拉罗切有限公司 | 作为腺苷受体配体的噻唑并吡啶衍生物 |
WO2005044793A2 (en) | 2003-10-31 | 2005-05-19 | Takeda Pharmaceutical Company Limited | Nitrogen-containing fused heterocyclic compounds |
CA2552914C (en) * | 2004-01-08 | 2010-09-14 | F.Hoffmann-La Roche Ag | Diaza-spiropiperidine derivatives |
SI1753760T1 (sl) * | 2004-05-24 | 2008-04-30 | Hoffmann La Roche | (4-metoksi-7-morfolin-4-il-benzotiazol-2-il)-amid4- hidroksi-4-metil-piperidin-1-karboksilne kisline |
KR100834179B1 (ko) * | 2004-05-24 | 2008-05-30 | 에프. 호프만-라 로슈 아게 | 4-하이드록시-4-메틸-피페리딘-1-카복실산(4-메톡시-7-모폴린-4-일-벤조티아졸-2-일)-아마이드 |
BRPI0513511A (pt) * | 2004-07-22 | 2008-05-06 | Hoffmann La Roche | derivados de benzotiazol |
JP2008506735A (ja) | 2004-07-22 | 2008-03-06 | エフ.ホフマン−ラ ロシュ アーゲー | 置換されているベンゾチアゾール類 |
UY29321A1 (es) | 2004-12-30 | 2006-03-31 | Janssen Pharmaceutica Nv | Piperazinilureas y piperidinilureas como moduladores de hidrolasa de amida de ácidos grasos |
CA2602444C (en) | 2005-03-23 | 2013-03-19 | F.Hoffmann-La Roche Ag | Acetylenyl-pyrazolo-pyrimidine derivatives as mglur2 antagonists |
WO2007039439A1 (en) | 2005-09-27 | 2007-04-12 | F.Hoffmann-La Roche Ag | Oxadiazolyl pyrazolo-pyrimidines as mglur2 antagonists |
US8841334B2 (en) | 2006-05-31 | 2014-09-23 | Abbvie Inc. | Compounds as cannabinoid receptor ligands and uses thereof |
JP2009538933A (ja) | 2006-05-31 | 2009-11-12 | アボット・ラボラトリーズ | カンナビノイド受容体リガンドとしての化合物およびその使用 |
US7910108B2 (en) * | 2006-06-05 | 2011-03-22 | Incyte Corporation | Sheddase inhibitors combined with CD30-binding immunotherapeutics for the treatment of CD30 positive diseases |
CA2655310A1 (en) * | 2006-06-22 | 2008-05-29 | Cv Therapeutics, Inc. | Use of a2a adenosine receptor agonists in the treatment of ischemia |
WO2008023720A1 (fr) * | 2006-08-23 | 2008-02-28 | Astellas Pharma Inc. | COMPOSÉ D'URÉE OU SEL DUDIT COMPOSé |
CL2007003827A1 (es) * | 2006-12-28 | 2008-09-26 | Actelion Pharmaceuticals Ltd | Compuestos derivados de n-(2-aza-biciclo(3.1.0)hex-3-ilmetil)amida; y su uso para prevenir o tratar la depresion, neurosis, esquizofrenia, ansiedad, adicciones, epilepsia, dolor, enfermedades cardiacas, entre otras. |
EP2142522A1 (en) | 2007-03-28 | 2010-01-13 | Abbott Laboratories | 1, 3-thiazol-2 (3h) -ylidene compounds as cannabinoid receptor ligands |
US7872033B2 (en) | 2007-04-17 | 2011-01-18 | Abbott Laboratories | Compounds as cannabinoid receptor ligands |
CA2683086A1 (en) | 2007-05-18 | 2008-11-18 | Abbott Laboratories | Color tunable light source |
KR20100017885A (ko) * | 2007-05-25 | 2010-02-16 | 얀센 파마슈티카 엔.브이. | 지방산 아미드 하이드롤라아제의 헤테로아릴-치환된 우레아 조절제 |
EP2178534A4 (en) | 2007-07-17 | 2011-03-30 | Merck Sharp & Dohme | SOLUBLE EPOXY HYDROLASE INHIBITORS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND PROCESSING METHODS |
US9193713B2 (en) | 2007-10-12 | 2015-11-24 | Abbvie Inc. | Compounds as cannabinoid receptor ligands |
JP2011511782A (ja) | 2008-02-12 | 2011-04-14 | アボット・ラボラトリーズ | 長期放出性ヒドロコドンアセトアミノフェンならびにその関連方法および用途 |
US8846730B2 (en) | 2008-09-08 | 2014-09-30 | Abbvie Inc. | Compounds as cannabinoid receptor ligands |
TW201016692A (en) | 2008-09-16 | 2010-05-01 | Abbott Lab | Novel compounds as cannabinoid receptor ligands |
US8598356B2 (en) * | 2008-11-25 | 2013-12-03 | Janssen Pharmaceutica Nv | Heteroaryl-substituted urea modulators of fatty acid amide hydrolase |
WO2010068453A1 (en) | 2008-11-25 | 2010-06-17 | Janssen Pharmaceutica Nv | Heteroaryl-substituted urea modulators of fatty acid amide hydrolase |
PA8854001A1 (es) | 2008-12-16 | 2010-07-27 | Abbott Lab | Compuestos novedosos como ligandos de receptores de canabinoides |
FR2945531A1 (fr) * | 2009-05-12 | 2010-11-19 | Sanofi Aventis | Derives de 7-aza-spiro°3,5!nonane-7-carboxylates, leur preparation et leur application en therapeutique |
US8901111B2 (en) | 2009-06-05 | 2014-12-02 | Janssen Pharmaceutica Nv | Aryl-substituted heterocyclic urea modulators of fatty acid amide hydrolase |
US20120083476A1 (en) | 2009-06-05 | 2012-04-05 | Janssen Pharmaceutica Nv | Heteroaryl-substituted spirocyclic diamine urea modulators of fatty acid amide hydrolase |
WO2011021645A1 (ja) * | 2009-08-19 | 2011-02-24 | 大日本住友製薬株式会社 | 2環性ウレア誘導体、またはその薬学的に許容される塩 |
UA108233C2 (uk) | 2010-05-03 | 2015-04-10 | Модулятори активності гідролази амідів жирних кислот | |
EP2875029B8 (en) * | 2012-07-18 | 2021-12-15 | University of Notre Dame du Lac | 5,5-heteroaromatic anti-infective compounds |
EP2991967A1 (en) * | 2013-03-20 | 2016-03-09 | F. Hoffmann-La Roche AG | Urea derivatives and their use as fatty-acid binding protein (fabp) inhibitors |
BR112015024113A2 (pt) | 2013-03-20 | 2017-07-18 | Hoffmann La Roche | derivados de uréia e seu uso como inibidores da proteína de ligação de ácido graxo (fabp) |
CA3083000A1 (en) | 2017-10-24 | 2019-05-02 | Yumanity Therapeutics, Inc. | Compounds and uses thereof |
WO2019141096A1 (zh) * | 2018-01-19 | 2019-07-25 | 四川科伦博泰生物医药股份有限公司 | 取代脲类化合物及其制备方法和用途 |
CN111205244B (zh) * | 2018-11-22 | 2023-08-18 | 上海科技大学 | 噻唑并环类化合物、其制备方法、中间体和应用 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US45615A (en) * | 1864-12-27 | Improvement in cultivators | ||
US3954766A (en) * | 1975-07-09 | 1976-05-04 | Stanford Research Institute | 1,4-Diazabicyclo[3.2.1]octanes |
EP0113219B1 (en) | 1982-12-21 | 1987-11-19 | Johnsen & Jorgensen (Plastics) Limited | Dispensing container |
IL151045A0 (en) | 2000-02-07 | 2003-04-10 | Abbott Gmbh & Co Kg | 2-benzothiazolyl urea derivatives and their use as protein kinase inhibitors |
NZ522928A (en) * | 2000-06-21 | 2005-05-27 | F | Benzothiazole derivatives |
US6599901B1 (en) * | 2001-11-19 | 2003-07-29 | Hoffman-La Roche Inc. | Pyridone substituted benzothiazole derivatives |
US6727247B2 (en) * | 2001-12-10 | 2004-04-27 | Hoffman-La Roche Inc. | Substituted benzothiazole amide derivatives |
-
2002
- 2002-12-03 US US10/308,338 patent/US6727247B2/en not_active Expired - Fee Related
- 2002-12-05 AU AU2002356626A patent/AU2002356626B2/en not_active Ceased
- 2002-12-05 DE DE60219682T patent/DE60219682T2/de not_active Expired - Lifetime
- 2002-12-05 MX MXPA04005444A patent/MXPA04005444A/es active IP Right Grant
- 2002-12-05 TW TW091135281A patent/TW200409628A/zh unknown
- 2002-12-05 CN CNA028246543A patent/CN1602196A/zh active Pending
- 2002-12-05 RU RU2004121166/15A patent/RU2311905C2/ru not_active IP Right Cessation
- 2002-12-05 PE PE2002001174A patent/PE20030759A1/es not_active Application Discontinuation
- 2002-12-05 PA PA20028559901A patent/PA8559901A1/es unknown
- 2002-12-05 AT AT02804578T patent/ATE359792T1/de active
- 2002-12-05 BR BR0214825-0A patent/BR0214825A/pt not_active Application Discontinuation
- 2002-12-05 EP EP02804578A patent/EP1455792B1/en not_active Expired - Lifetime
- 2002-12-05 PL PL02371063A patent/PL371063A1/xx not_active Application Discontinuation
- 2002-12-05 WO PCT/EP2002/013761 patent/WO2003049741A1/en active IP Right Grant
- 2002-12-05 ES ES02804578T patent/ES2283652T3/es not_active Expired - Lifetime
- 2002-12-05 CA CA002469596A patent/CA2469596A1/en not_active Abandoned
- 2002-12-05 JP JP2003550790A patent/JP4245483B2/ja not_active Expired - Fee Related
- 2002-12-05 KR KR1020047008868A patent/KR100659793B1/ko not_active IP Right Cessation
- 2002-12-06 AR ARP020104739A patent/AR037731A1/es unknown
- 2002-12-09 GT GT200200266A patent/GT200200266A/es unknown
-
2003
- 2003-10-23 US US10/691,770 patent/US7019001B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
RU2311905C2 (ru) | 2007-12-10 |
US7019001B2 (en) | 2006-03-28 |
DE60219682T2 (de) | 2008-01-17 |
BR0214825A (pt) | 2004-09-14 |
AU2002356626B2 (en) | 2007-11-29 |
AU2002356626A1 (en) | 2003-06-23 |
US20040229893A1 (en) | 2004-11-18 |
CA2469596A1 (en) | 2003-06-19 |
KR20040065576A (ko) | 2004-07-22 |
RU2004121166A (ru) | 2005-05-10 |
US20030149036A1 (en) | 2003-08-07 |
CN1602196A (zh) | 2005-03-30 |
DE60219682D1 (de) | 2007-05-31 |
MXPA04005444A (es) | 2004-10-11 |
TW200409628A (en) | 2004-06-16 |
JP2005516006A (ja) | 2005-06-02 |
EP1455792B1 (en) | 2007-04-18 |
PA8559901A1 (es) | 2003-09-05 |
US6727247B2 (en) | 2004-04-27 |
ATE359792T1 (de) | 2007-05-15 |
ES2283652T3 (es) | 2007-11-01 |
EP1455792A1 (en) | 2004-09-15 |
PL371063A1 (en) | 2005-06-13 |
KR100659793B1 (ko) | 2006-12-19 |
JP4245483B2 (ja) | 2009-03-25 |
WO2003049741A1 (en) | 2003-06-19 |
AR037731A1 (es) | 2004-12-01 |
GT200200266A (es) | 2003-07-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE20030759A1 (es) | Uso de ureas de benzotiazoles | |
AR029215A1 (es) | Derivados de benzazol y tautomeros de los mismos utiles en el tratamiento de desordenes en los sistemas de autoinmunidad y neuronales, uso de dichos derivados en la preparacion de composiciones farmaceuticas aplicables en el tratamiento de dichos desordenes, metodo prar inhibir la expresion y/o acti | |
AR004516A1 (es) | Derivados de pirimidina, su uso, procedimientos para prepararlos y medicamentos que los contienen | |
PE20010039A1 (es) | Derivados de esteres del acido carbamico como agonistas y/o antagonistas del receptor metabotropico del glutamato | |
ES2060585T3 (es) | 1,2,3,3a,8,8a-hexahidro-1,3a,8-trimetilpirrolo(2,3-b)indoles, un procedimiento para su preparacion y su uso como medicamentos. | |
AR037983A1 (es) | Derivados de pirido [2,1-a] isoquinolina | |
PE20010854A1 (es) | USO DE DERIVADOS DE PIRIMIDINA 4 SUSTITUIDOS COMO ANTAGONISTAS DE LOS RECEPTORES DE GLUTAMATO mGluR1 | |
PE20001467A1 (es) | Derivados de 4-fenilpiridina como antagonistas del receptor de neuroquinina | |
EA200301306A1 (ru) | Производные 1-фенилсульфонил-1,3-дигидро-2h-индол-2-она, их получение и их терапевтическое применение | |
PE20030922A1 (es) | Derivados de piridina y quinolina | |
AR051202A1 (es) | Derivados heterociclicos y su uso como inhibidores de la estearoil-coa desaturasa | |
PE20071325A1 (es) | Derivados de n-heteroaril-carboxamidas triciclicas que contienen un resto bencimidazol, su preparacion y su aplicacion en terapeutica | |
DE60042762D1 (de) | Zwischenprodukte für die Herstellung von Harnstoffderivaten mit Muskarinrezeptor-antagonistischer Aktivität | |
ES2184772T3 (es) | Derivados de bifenilo, procedimiento para su preparacion y su utilizacion como medicamentos. | |
PE20030735A1 (es) | Derivados de benzotiazol | |
ATE219077T1 (de) | Endothelin antagoniste | |
PE20030761A1 (es) | Derivados del 7-amino-benzotiazol | |
AR247886A1 (es) | Procedimiento para la preparacion de un compuesto biciclico heterociclico y una sal farmaceuticamente aceptable del mismo | |
PE1998A1 (es) | DERIVADOS DE BENZO [g] QUINOLINA | |
ES2138983T3 (es) | Uso de derivados del acido 2-(n-(2-aminoetil)amino)-acetico para el tratamiento de enfermedades condicionadas por glicosilacion no enzimatica. | |
PE20030867A1 (es) | Derivados de quinazolinona | |
ES2095855T3 (es) | Derivados de tetrahidrobencimidazol. | |
PT87866A (pt) | Processo para a preparacao de pirrolidinas e hexa-hidro-1h-azepinas substituidas por {(heterociclico biciclico) metilo e -hetero} | |
AR012870A1 (es) | Derivados de ergolina ([6ar, 9r, 10ar]-6-[4-(5-bromo-7-metil-4,6,6a,7,8,9, 10,10a-octahidro-indol[4,3-fg]quinolin-9-carbonil)-piperazin-1-il]-1-metil-1h-piridin-2-ona), proceso para su produccion, composicion farmaceutica, y su uso para la fabricacion de un medicamento para el tratamiento de depresi | |
AR010984A1 (es) | Nuevos esteres de la pleuromutilina, y el acido 1-azabiciclo-4- carbanilcarbanico; procedimiento para su preparacion y composicionesfarmaceuticas que los contienen. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant, registration | ||
FD | Application declared void or lapsed |